close

Agreements

Date: 2011-11-08

Type of information: Development agreement

Compound: antibodies used in dementia diagnosis

Company: ADx NeuroSciences (Belgium) KU Leuven (Belgium)

Therapeutic area: Neurodegenerative diseases

Type agreement:

development
licensing

 

 

Action mechanism:

Disease:

Details:

ADx NeuroSciences, a new biotech company focused on the development of novel (bio)markers for use in the diagnosis of dementia, such as Alzheimer’s, Parkinson’s and other neurodegenerative diseases, has entered into exclusive license agreement with K.U.Leuven, the academic founder of the company, for the development of antibodies used in dementia diagnosis. The license agreement grants ADx NeuroSciences exclusive worldwide rights to further develop and commercialise certain antibodies which selectively bind phosphorylated Tau aggregates.

Current tests to diagnose patients with Alzheimer’s disease are unable to indicate the prognosis of the disease. As a consequence, the pharma industry as well as clinicians will urgently need novel markers to be able to identify patients and to predict how the disease evolves. In response to this demand, ADx NeuroSciences aims to commercialise diagnostic products for neurodegenerative disorders that are developed in close collaboration with pharma.

Financial terms:

Latest news:

Is general: Yes